Prostate Cancer Clinical Trial

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Summary

Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).

View Full Description

Full Description

This open-label, pilot trial aims to evaluate the feasibility of Sipuleucel-T given in three doses at weeks 0, 2, and 12-14; and to investigate the changes in immune response in mCRPC patients who are getting an extended course of Sipuleucel-T treatment.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men ≥ 18 years of age
Prostate cancer with history of metastasis
Candidates for Sipuleucel-T treatment are defined as those with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy of ≥ 6 months

Exclusion Criteria:

Previously received Sipuleucel-T (Provenge®)
Known malignancies other than prostate cancer likely to require treatment within 6 months following registration
A requirement for systemic immunosuppressive therapy (>10mg Prednisone daily or equivalent)
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to Sipuleucel-T or GM-CSF
Any infection requiring antibiotic therapy within 1 week prior to registration

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT05806814

Recruitment Status:

Not yet recruiting

Sponsor:

University of Oklahoma

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stephenson's Cancer Center
Oklahoma City Oklahoma, 73114, United States More Info
Kelly Stratton, MD
Contact
405-271-6900
[email protected]
Kelly Stratton, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT05806814

Recruitment Status:

Not yet recruiting

Sponsor:


University of Oklahoma

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.